Phase 1, Randomized, Open Label, Three-arm, Single Dose, Parallel Group Study to Compare AZD7442 (AZD8895 + AZD1061) Pharmacokinetic Exposure Following Intramuscular Administration as a Co-formulation Versus Administration From Two Separate Vials of the Individual Monoclonal Antibodies in Adult Healthy Participants
Latest Information Update: 27 Nov 2024
At a glance
- Drugs Cilgavimab/tixagevimab (Primary) ; Cilgavimab; Tixagevimab
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 10 Aug 2023 Status changed from active, no longer recruiting to completed.
- 12 Aug 2022 Planned End Date changed from 28 Jul 2023 to 21 Jul 2023.
- 12 Aug 2022 Planned primary completion date changed from 28 Jul 2023 to 21 Jul 2023.